CWCong Wang

Cong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cong Wang has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Pan

    Department of Breast Surgery & General Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

    4 shared publications
  • Shui Wang

    Jiangsu Cancer Hospital 3 Department of Breast Surgery Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China

    4 shared publications
  • Wenbin Zhou

    Department of Breast Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing China

    4 shared publications
  • Chun Lu

    Department of Microbiology Nanjing Medical University Nanjing 211166 P. R. China

    3 shared publications
  • Xiaoyu Qi

    Department of Gynecology Women's Hospital of Nanjing Medical University Nanjing Women and Children's Healthcare Hospital Nanjing Medical University Nanjing 210004 P. R. China

    3 shared publications
  • Yue Sun

    Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

    3 shared publications

Latest Publications

  • Open Access

    Integrated transcriptome study reveals a stress response state CD4 +T cells related to immune tolerance in breast cancer

    by Jinyuan Gu, Qi Qi, Xinrui Mao, Rong Cong, Yue Sun, Xinyu Tang, Xiaoxiang Guan, Ji Wang, Muxin Yu, Shui Wang, et al.

    Lymph node status is of great clinical importance in tumor staging and prognosis where antitumoral immunity is generated and preserved. However, the immune

  • Primary mucinous cystadenocarcinoma of the breast commonly harbours TP53 mutations and PI3K/AKT pathway alterations

    by Cheng Xu, Jing Wu, Ying Ding, Zhihong Zhang, Cong Wang

    Primary mucinous cystadenocarcinoma (MCA) of the breast is an invasive breast carcinoma characterized by cystic structures lined by tall columnar cells with abundant intracytoplasmic mucin, resembling pancreatobiliary or ovarian mucinous cystadenocarcinoma. Fewer than 50 cases have been reported worldwide so far. In this series, we describe the clinical, morphologic, immunohistochemical, and molecular features of 5 cases of breast MCA. The median age of the patients was 54 years (range: 53 to 64 years) and invasive size was 2 mm to 30 mm (our study reported the smallest invasive size to date in case 5). DCIS was present in 4 of 5 cases. Despite the prevailing view that breast MCA may be indolent, our cases exhibit robust growth, characterized by a relatively high Ki67 index, brisk mitosis, and 1 case of micrometastasis of axillary lymph node micrometastasis. Moreover, we conducted large panel sequencing on 4 cases, and emphasize their molecular essence; that is, breast MCA exhibits a high frequency of TP53 mutations and PI3K/AKT pathway alterations. A review of the literature on previous and current genomic profiles indicates that MCAs are similar to triple-negative breast cancer (TNBC). In our opinion, patients with breast MCA should receive precise clinical treatment similarly to invasive breast carcinoma of no special type, with careful consideration of tumor grade, stage, immunophenotype, and genomic profile, and we believe that PI3K-targeted therapies may play a valuable role in treating this rare tumor.

  • Open Access

    De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial

    by Hong Pan, Yi Ren, Mengyao Zha, Mingduo Liu, Xiaoan Liu, Hui Xie, Xiaoming Zha, Yi Zhao, Lin Chen, Tiansong Xia, et al.


  • Open Access

    HPV E6/E7‐Induced Acetylation of a Peptide Encoded by a Long Non‐Coding RNA Inhibits Ferroptosis to Promote the Malignancy of Cervical Cancer

    by Xiaoyu Qi, Jing Zhou, Xinyue Wang, Yan Shen, Yuxun Cao, Liangzi Jiang, Miaomiao Shen, Haoran Zhang, Tianjiao Wang, Pengjun Wei, et al.

    Although a fraction of functional peptides concealed within long non‐coding RNAs (lncRNAs) is identified, it remains unclear whether lncRNA‐encoded peptides are involved in the malignancy of cervical cancer (CC). Here, a 92‐amino acid peptide is discovered, which is named TUBORF, encoded by lncRNA TUBA3FP and highly expressed in CC tissues. TUBORF inhibits ferroptosis to promote the malignant proliferation of CC cells. Mechanistically, human papillomavirus (HPV) oncogenes E6 and E7 upregulate TUBORF through CREB‐binding protein (CBP)/E1A‐binding protein p300 (p300)‐mediated histone H3 lysine 27 acetylation (H3K27ac) of lncTUBA3FP enhancer. Furthermore, E6 and E7 elevate and recruit acetyltransferase establishment of sister chromatid cohesion N‐acetyltransferase 1 (ESCO1) to bind to and acetylate TUBORF, which facilitates the degradation of immunity‐related GTPase Q (IRGQ) via a ubiquitin‐proteasome pathway, resulting in the inhibition of ferroptosis and promotion of the malignant proliferation of CC cells. Importantly, silencing ESCO1 or TURORF amplifies anticancer effects by paclitaxel both in CC cells and in vivo. These novel findings reveal oncopeptide TUBORF and its acetyltransferase ESCO1 as important regulators of ferroptosis and tumorigenesis during cervical cancer pathogenesis and establish the scientific basis for targeting these molecules for treating CC.


  • Open Access

    Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining

    by Wenting Gan, Xue Han, Yuxi Gong, Yefan Yang, Cong Wang, Zhihong Zhang

    Background: Current diagnostic criteria of adrenocortical neoplasms are mostly based on morphology. The utility of immunohistochemistry (IHC) and histochemistry is limited. Materials and methods: To evaluate the diagnostic and prognostic utility of clinicopathological features, morphology, ancillary biomarkers, and reticular histochemistry in adrenocortical neoplasms. We examined 28 adrenocortical carcinomas (ACCs) and 50 adrenocortical adenomas (ACAs) obtained from pathology archives. Clinical data were retrieved from medical records. Two pathologists independently assessed hematoxylin and eosin-stained slides, employing modified Weiss criteria for all tumors and Lin-Weiss-Bisceglia criteria for oncocytic variants. Immunohistochemical markers (Calretinin, alpha-inhibin, MelanA, SF-1, Ki-67, PHH3, IGF-2, β-catenin, P53, CYP11B1, CYP11B2, MLH1, MSH2, MSH6, PMS2, EPCAM) and Gomori’s Silver histochemistry were applied. Statistical analysis utilized SPSS Statistics 26. Results: ACCs exhibited larger tumor sizes (PP = 0.031) compared to ACAs. Parameters of modified Weiss criteria and angioinvasion demonstrated diagnostic value for ACCs. Six immunohistochemical antibodies((MelanA, Ki-67, IGF-2, β-catenin, P53 and CYP11B1) and reticulin framework alterations showed diagnostic value. Notably, Ki-67 and reticulin staining were most recommended. Evident reticulin staining was frequently present in ACCs (PP<0.001). Twenty-one conventional and seven oncocytic entities showed different necrosis frequencies. Symptoms and Ki-67 index ≥ 30% were prognostic for ACCs, correlating with shorter survival. Conclusions: This study emphasizes the diagnostic value of reticulin framework alterations and a high Ki-67 index. Markers such as CYP11B1, IGF2, P53, β-catenin and MelanA also contribute to the diagnosis of ACCs. Symptoms and Ki-67 index ≥ 30% predict shorter survival. These findings encourges the use of ancillary markers such as reticulin histochemistry and Ki-67 in the workup of evaluations of adrenocortical neoplasms.


  • Open Access

    Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer

    by Jinyuan Gu, Jiaming Wang, Yue Sun, Xinrui Mao, Chao Qian, Xinyu Tang, Ji Wang, Hui Xie, Lijun Ling, Yi Zhao, et al.

    Introduction: Locoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.Methods: We retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.Results: We found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup (p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup (p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor (p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors (p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors (p = 0.037).Conclusion: Our study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.


  • Open Access

    Morphological and molecular pathological features of the breast carcinoma with choriocarcinomatous features: A case report and a literature review

    by Jingchun Xu, Yi Xu, Cheng Xu, Cong Wang

    Here we present a rare case of breast cancer with both invasive ductal carcinoma and choriocarcinoma components in a 55-year-old woman. Firstly, the serum human chorionic gonadotropin level showed 15.9mIU/ml preoperatively. And adequate immunohistochemical tests were performed on the specimen. Secondly, High-throughput sequencing was performed to detect the molecular characteristics of the two components, respectively. Then, DNA short tandem repeat (STR) analysis confirmed the homology of the two components, indicating the somatic origin of choriocarcinoma components. Finally, the clinical course and pathological characteristics of the case were reviewed and a literature search for other cases was performed.

  • Open Access

    Successful pregnancy via in vitro fertilization in a primary infertile woman with primary lymphoma of the fallopian tube after surgery: A case report and literature review

    by Jie Mm Zhang, Zhen Hou, Jie Huang, Wei Xu, Cong Wang, Xiang Ma, Nan Lu, Jiayin Liu, Yundong Mao, Yi Qian

    Rationale: Primary extranodal marginal zone B-cell lymphomas of the fallopian tube is extremely rare. It is a great challenge for fertility and gynecology doctors to manage such cases and also fulfil the reproductive demands of these young women. Patient concerns: A 30-year-old woman consulted for a 5-year primary infertility. Diagnosis: According to the Ann Arbor staging system, a stage IE extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma was diagnosed for this patient based on tumor pathology, bone marrow biopsy, hysteroscopy and whole-body positron emission tomography imaging. She also had endometriosis based on laparoscopy. Interventions: The patient underwent a laparoscopic bilateral salpingostomy without additional surgery or radiotherapy and chemotherapy for fertility preservation, and received 5 months of long-acting gonadotropin releasing hormone agonist treatment for endometriosis. Outcomes: Two years after the surgery, the patient delivered a healthy neonate through in vitro fertilization-embryo transfer procedures. The patient is now 3 years post-op and 1 year post-delivery, long-term follow-up suggested that the patient remained cancer-free up till now. Lessons: More care should be taken when the newly diagnosed mass is combined with a rather high serum CA-125 level. Although endometriosis and ovarian cancer are more common, lymphoma cannot be ruled out.


  • An oncogenic viral interferon regulatory factor upregulates CUB domain-containing protein 1 to promote angiogenesis by hijacking transcription factor lymphoid enhancer-binding factor 1 and metastasis suppressor CD82

    by Wan Li, Qingxia Wang, Xiaoyu Qi, Hongmei Lu, Yuheng Chen, Jiale Shi, Fei Wang, Ziyu Wang, Yao Lu, Zhongmou Lu, et al.

    Kaposi’s sarcoma (KS), a highly angiogenic and invasive vascular tumor, is the most common AIDS-associated cancer caused by KS-associated herpesvirus (KSHV) infection. We have recently shown that KSHV-encoded viral interferon regulatory factor 1 (vIRF1) contributes to KSHV-induced cell motility (PLoS Pathog. 15:e1007578, 2019). However, the role of vIRF1 in KSHV-induced angiogenesis remains unknown. Here, using two in vivo angiogenesis models including the chick chorioallantoic membrane assay (CAM) and the matrigel plug angiogenesis assay in mice, we show that vIRF1 promotes angiogenesis by upregulating CUB domain (for complement C1r/C1s, Uegf, Bmp1) containing protein 1 (CDCP1). Mechanistically, vIRF1 enhances the expression of transcription factor lymphoid enhancer-binding factor 1 (Lef1) and binds to Lef1 to promote CDCP1 transcription. Meanwhile, vIRF1 degrades metastasis suppressor CD82 through an ubiquitin–proteasome pathway by recruiting E3 ubiquitin ligase AMFR to CD82, which protects CDCP1 from CD82-mediated, palmitoylation-dependent degradation. CDCP1 activates AKT signaling, which is required for vIRF1-induced cell motility but not angiogenesis. Our results illustrate that, by hijacking Lef1 and CD82, vIRF1 upregulates CDCP1 to promote angiogenesis and cell invasion. These novel findings demonstrate the vIRF1 targets multiple cellular proteins and pathways to promote the pathogenesis of KS, which could be attractive therapeutic targets for KSHV-induced malignancies.